Literature DB >> 28918569

Highlights from the Ninth International Symposium of Thrombosis and Anticoagulation (ISTA IX), October 15, 2016, Salvador, Bahia, Brazil.

Renato D Lopes1, Patricia O Guimarães2, Elaine Hylek3, Gilson S Feitosa-Filho4,5,6, Luiz Ritt4,7, Nivaldo Filgueiras8,9, Eduardo Darzé7, Mario S Rocha4,10, Luis P Magalhães11, Antonio Carlos Sobral Sousa12,13, Luis Claudio Correia4,14, Lucas Hollanda Oliveira14,15, David A Garcia16.   

Abstract

To discuss and share knowledge about advances in the care of patients with thrombotic disorders, the Ninth International Symposium of Thrombosis and Anticoagulation was held in Salvador, Bahia, Brazil, on October 15, 2016. This scientific program was developed by clinicians for clinicians and was promoted by two major clinical research institutes-the Brazilian Clinical Research Institute and the Duke Clinical Research Institute of the Duke University School of Medicine. Comprising academic presentations and open discussion, the symposium had as its primary goal to educate, motivate, and inspire internists, cardiologists, hematologists, and other physicians by convening national and international visionaries, thought-leaders, and dedicated clinician-scientists. This paper summarizes the symposium proceedings.

Entities:  

Keywords:  Antithrombotic therapy; Clinical research; Guidelines; Thrombosis

Mesh:

Substances:

Year:  2017        PMID: 28918569     DOI: 10.1007/s11239-017-1551-8

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  55 in total

1.  Intravenous thrombolysis in a stroke patient taking dabigatran.

Authors:  Vivien H Lee; James J Conners; Shyam Prabhakaran
Journal:  J Stroke Cerebrovasc Dis       Date:  2012-05-16       Impact factor: 2.136

2.  European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.

Authors:  Hein Heidbuchel; Peter Verhamme; Marco Alings; Matthias Antz; Werner Hacke; Jonas Oldgren; Peter Sinnaeve; A John Camm; Paulus Kirchhof
Journal:  Europace       Date:  2013-05       Impact factor: 5.214

3.  Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.

Authors:  E Magnus Ohman; Matthew T Roe; P Gabriel Steg; Stefan K James; Thomas J Povsic; Jennifer White; Frank Rockhold; Alexei Plotnikov; Hardi Mundl; John Strony; Xiang Sun; Steen Husted; Michal Tendera; Gilles Montalescot; M Cecilia Bahit; Diego Ardissino; Héctor Bueno; Marc J Claeys; Jose C Nicolau; Jan H Cornel; Shinya Goto; Róbert Gábor Kiss; Ümit Güray; Duk-Woo Park; Christoph Bode; Robert C Welsh; C Michael Gibson
Journal:  Lancet       Date:  2017-03-18       Impact factor: 79.321

Review 4.  Left atrial appendage closure for thromboembolism prevention in patients with atrial fibrillation: advances and perspectives.

Authors:  Bin Kong; Yu Liu; He Huang; Hong Jiang; Congxin Huang
Journal:  J Thorac Dis       Date:  2015-02       Impact factor: 2.895

5.  Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry.

Authors:  Vivek Y Reddy; David Holmes; Shephal K Doshi; Petr Neuzil; Saibal Kar
Journal:  Circulation       Date:  2011-01-17       Impact factor: 29.690

6.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.

Authors:  Werner Hacke; Markku Kaste; Erich Bluhmki; Miroslav Brozman; Antoni Dávalos; Donata Guidetti; Vincent Larrue; Kennedy R Lees; Zakaria Medeghri; Thomas Machnig; Dietmar Schneider; Rüdiger von Kummer; Nils Wahlgren; Danilo Toni
Journal:  N Engl J Med       Date:  2008-09-25       Impact factor: 91.245

7.  D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial.

Authors:  A T Cohen; T E Spiro; A C Spyropoulos; Y H Desanctis; M Homering; H R Büller; L Haskell; D Hu; R Hull; A Mebazaa; G Merli; S Schellong; V F Tapson; P Burton
Journal:  J Thromb Haemost       Date:  2014-04       Impact factor: 5.824

8.  The left atrial appendage: from embryology to prevention of thromboembolism.

Authors:  Giuseppe Patti; Vittorio Pengo; Rossella Marcucci; Plinio Cirillo; Giulia Renda; Francesca Santilli; Paolo Calabrò; Alberto Ranieri De Caterina; Ilaria Cavallari; Elisabetta Ricottini; Vito Maurizio Parato; Giacomo Zoppellaro; Giuseppe Di Gioia; Pietro Sedati; Vincenzo Cicchitti; Giovanni Davì; Enrica Golia; Ivana Pariggiano; Paola Simeone; Rosanna Abbate; Domenico Prisco; Marco Zimarino; Francesco Sofi; Felicita Andreotti; Raffaele De Caterina
Journal:  Eur Heart J       Date:  2017-03-21       Impact factor: 29.983

9.  Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States.

Authors:  William L Baker; Deborah A Cios; Stephen D Sander; Craig I Coleman
Journal:  J Manag Care Pharm       Date:  2009-04

10.  Edoxaban versus warfarin in patients with atrial fibrillation.

Authors:  Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.